CRMD Stock Summary and Trading Ideas (Cormedix | NASDAQ:CRMD)

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Cormedix trades on the NASDAQ stock market under the symbol CRMD.

As of July 24, 2026, CRMD stock price declined to $7.87 with 586,702 million shares trading.

CRMD has a beta of 0.71, meaning it tends to be less sensitive to market movements. CRMD has a correlation of 0.02 to the broad based SPY ETF.

CRMD has a market cap of $617.34 million. This is considered a Small Cap stock.

Last quarter Cormedix reported $127 million in Revenue and $.43 earnings per share. This beat revenue expectation by $21 million and exceeded earnings estimates by $.10.

In the last 3 years, CRMD traded as high as $17.43 and as low as $2.57.

The top ETF exchange traded funds that CRMD belongs to (by Net Assets): VTI, IWM, VXF, IWN, CALF.

CRMD has underperformed the market in the last year with a price return of -31.6% while the SPY ETF gained +17.7%. However, in the short term, CRMD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.1% vs +3.8% return in SPY. But in the last 2 weeks, CRMD shares have been beat by the market, returning -6.3% compared to an SPY return of -2.1%.

CRMD support price is $7.75 and resistance is $8.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRMD shares will trade within this expected range on the day.